Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharma Adapts Ovarian Cancer Drugs Amid Genomics Revolution

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Astra Zeneca hustles on genomic analyses of PARP inhibitor olaparib after drug fails to improve overall survival in a Phase II ovarian cancre trial, which could signify a revival. Meanwhile, Avastin lead investigator defends anti-angiogenesis approach, considering tremendous diversity of the relatively uncommon disease.

You may also be interested in...



Merck/Endocyte Mulling Vintafolide’s Future After Failure In Ovarian Cancer

Endocyte is potentially propelled back to a Phase I company after its nearest commercial prospect flops and its collaboration with Merck is expected to disintegrate now that the drug missed PFS in ovarian cancer.

Merck/Endocyte Mulling Vintafolide’s Future After Failure In Ovarian Cancer

Endocyte is potentially propelled back to a Phase I company after its nearest commercial prospect flops and its collaboration with Merck is expected to disintegrate now that the drug missed PFS in ovarian cancer.

New PARP On The Block: BioMarin Starts Phase III, Could Prove To Be Best-In-Class

Class’s comeback gets more fuel at AACR/NCI/EORTC targeted therapies meeting. Evidence indicates BioMarin may have the most powerful PARP inhibitor, though AstraZeneca and Tesaro are slightly further in development.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS005160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel